Literature DB >> 8439946

Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls.

J Brockmöller1, R Kerb, N Drakoulis, M Nitz, I Roots.   

Abstract

Glutathione S-transferase class mu (GSTM1) is known to detoxify certain carcinogens or their activated metabolites. In a previous study using phenotyping methods, individuals genetically devoid of this enzyme activity were significantly overrepresented among lung cancer patients compared to controls, suggesting that this trait is a risk factor for lung cancer. Here, GST class mu status has been determined both pheno- and genotypically, i.e., (a) by ex vivo measurement of trans-stilbene oxide conjugation in lymphocytes, (b) by GSTM1 quantification in blood using an immunoassay, and (c) by the application of polymerase chain reaction to genomic DNA with characterization of an inactivating mutation responsible for the null allele and a G/C single base allelic variance corresponding to the polymorphism of GSTM1 isoenzymes mu and psi, respectively. One hundred seventeen lung cancer patients and 155 control patients were studied. The two groups were of German origin and were similar with respect to age, sex, smoking history, and catchment area. In about 97% of cases, the three methods of assigning activity type of GSTM1 gave corresponding results. By genotype, 55 of 117 lung cancer patients (47.0%) and 73 of 155 control patients (47.1%) were GSTM1 active. The control group was confirmed by analysis of GSTM1 genotype in 200 further, independently studied reference patients; 101 of them were GSTM1 active (50.5%). Thus, the hypothesis of heritable GSTM1 deficiency as a host factor predisposing to lung cancer proved inappropriate. Detailed analysis of subgroups with respect to smoking habits, age, and sex failed to reveal an impact of GST class mu genotype on lung cancer risk. Among the total of 272 patients studied, 36 individuals carried at least one psi allele; however, no unexpected frequency distribution was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439946

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1.

Authors:  Jian-Chao Bian; Fu-Ming Shen; Li Shen; Tian-Ru Wang; Xiao-Hong Wang; Gong-Chao Chen; Jin-Bing Wang
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

3.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

4.  The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.

Authors:  M M T J Broekman; D R Wong; G J A Wanten; H M Roelofs; C J van Marrewijk; O H Klungel; A L M Verbeek; P M Hooymans; H-J Guchelaar; H Scheffer; L J J Derijks; M J H Coenen; D J de Jong
Journal:  Pharmacogenomics J       Date:  2017-01-03       Impact factor: 3.550

Review 5.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 6.  Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer.

Authors:  Peter N Lee; Barbara A Forey; Katharine J Coombs
Journal:  BMC Cancer       Date:  2012-09-03       Impact factor: 4.430

7.  Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.

Authors:  Doaa H S Attia; Mervat Eissa; Lamees A Samy; Rasha A Khattab
Journal:  Clin Rheumatol       Date:  2020-07-13       Impact factor: 2.980

8.  Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans.

Authors:  Ted R Mikuls; Tricia Levan; Karen A Gould; Fang Yu; Geoffrey M Thiele; Kimberly K Bynote; Doyt Conn; Beth L Jonas; Leigh F Callahan; Edwin Smith; Richard Brasington; Larry W Moreland; Richard Reynolds; Angelo Gaffo; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2012-03

9.  Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.

Authors:  P David Josephy
Journal:  Hum Genomics Proteomics       Date:  2010-06-13

10.  Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1.

Authors:  K A McGlynn; E A Rosvold; E D Lustbader; Y Hu; M L Clapper; T Zhou; C P Wild; X L Xia; A Baffoe-Bonnie; D Ofori-Adjei
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.